Bisquinoline antimalarials: Their role in malaria chemotherapy

International Journal for Parasitology

Volumn 29, Issue 3, 1999, Pages 367-379

  Raynes, Kaylene ^a  

^a LA TROBE UNIVERSITY   (Australia)

Author keywords

Bisquinolines; Chloroquine; Drug resistance; Haem polymerisation; Malaria; Quinolineantimalarials

Indexed keywords

12278 RP; 12494 RP; 4 AMINOQUINOLINE DERIVATIVE; AMILORIDE; AMODIAQUINE; CHLOROQUINE; CHLORPROMAZINE; DESIPRAMINE; HEME; MEFLOQUINE; PAMAQUINE; PIPERAQUINE; QUININE; QUINOLINE DERIVATIVE; SONTOQUINE; UNCLASSIFIED DRUG; VERAPAMIL; WR 268688;

ANTIMALARIAL ACTIVITY; CONTROLLED STUDY; CROSS RESISTANCE; DRUG DESIGN; DRUG MECHANISM; DRUG SYNTHESIS; HUMAN; LIFE CYCLE; MALARIA CONTROL; MALARIA FALCIPARUM; MULTIDRUG RESISTANCE; PLASMODIUM FALCIPARUM; REVIEW;

CINCHONA PUBESCENS;

EID: 0032959813     PISSN: 00207519     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0020-7519(98)00217-3     Document Type: Article

References (90)

1. Turner RB, Woodward RB. The alkaloids. New York: Academic Press, 1953.
2. Thompson PE, Werbal LE. Antimalarial agents. New York: Academic Press, 1972.
3. Loeb RF, Clark WM, Coatney GR, et al. Activity of new antimalarial agents, chloroquine (SN 7618). J Am Med Assoc 1946;10:1069-1070.
4. Zucker RJ, Campbell CC. Antimalarial chemotherapy; a relentless challenge. Curr Opin Infect Dis 1995;8:455-460.
5. Nosten F, Van Vugt M. Malaria: still no vaccine and very few drugs. Curr Opin Infect Dis 1996;9:429-434.
6. Coatney GR, Cooper WC, Eddy NB, Greenberg J. Survey of antimalarial agents. Public Health Monograph 9. Washington, DC: US Government Printing Office, 1953;9.
7. Slater AFG. Chloroquine - mechanism of drug-action and resistance in Plasmodium falciparum. Pharmacol Ther 1993;57:203-235.
8. Fu S, Bjorkman A, Wahlin B, Ofori-Adjei D, Ericisson O, Sjoqvist F. In vivo activity of chloroquine, desethylated chloroquine and pyronaridine against Plasmodium falciparum. J Clin Invest 1986;22:93-99.
9. Hawley SR, Bray PG, O'Neill PM, Park BK, Ward SA. The role of drug accumulation in 4-aminoquinoline antimalarial potency. Biochem Pharmacol 1996;52:723-733.
10. White NJ, Looareesuwan S, Edwards G, et al. Pharmacokinetics of intravenous amodiaquine. Br J Clin Pharmacol 1987;23:127-135.
11. White NJ. Can amodiaquine be resurrected? Lancet 1996;348:1184-1185.
12. Davidson MW, Griggs BG, Boykin D, Wilson WD. Mefloquine, a clinically useful quinolinemethanol antimalarial which does not significantly bind to DNA. Nature 1975;254:632-634.
13. White NJ. Mefloquine in the prophylaxis and treatment of falciparum malaria. Br Med J 1994;308:286-287.
14. Li Y, Hu Y, Huang HZ, et al. Hydroxylpiperaquine in the treament of falciparum malaria. Chin Med J 1981;94:301-302.
15. Lin C, Feny-yi Q, Yan-chang Z. Field observations on the antimalarial piperaquine. Chin Med J 1982;95:281-286.
16. Lin C. Recent studies on the antimalarial efficacy of piperaquine and hydroxyl piperaquine. Chin Med J 1991;104:161-164.
17. Vennerstrom J, Ellis WY, Ager AL, Anderson SL, Gerena L, Milhous WK. Bisquinolines, N,N′-bis(7-chloroquinoline-4-yl)alkanediamines with potential against chloroquine resistant malaria. J Med Chem 1992;35:2129-2134.
18. Basco LK, Anderson SL, Milhous WK, Vennerstrom J. In vitro activity of Bisquinoline WR 268, 668 against African clones and isolates of Plasmodium falciparum. Am J Trop Med Hyg 1994;50:200-205.
19. Raynes KJ, Galatis D, Cowman AF, Tilley L, Deady LW. Synthesis and activity of some antimalarial bisquinolines. J Med Chem 1995;38:204-206.
20. Ridley RG, Hofheinz H, Matile C, et al. 4-Aminoquinoline analogs of chloroquine with shortened sidechains retain activity against chloroquine resistant Plasmodium falciparum. Antimicrob Agents Chemother 1996;40:1846-1854.
21. Hofheinz W, Masciadri R. Bisquinolines for the treatment of malaria. Chem Abs 1996;124:260861g.
22. Ridley RG, Matile H, Jaquet C et al. Antimalarial activity of the bisquinoline Irans N,N′-bis(7-chloroquinolin-4-yl)cyclohexan-1,2-diamine: comparison of the two steroisomers and detailed evaluation of the S,S enantiomer, Ro 47-7737. Antimicrob Agents Chemother 1997;41:677-86.
23. Hofheinz W, Leupin W. N,N′-Bis(quinolin-4-yl)diamine derivatives, their preparation and their use as antimalarials. Chem Abs 1996;124:260860f.
24. Raynes KJ, Foley M, Tilley L. Novel bisquinoline antimalarials, antimalarial avtivity and inhibition of haem polymerisation. Mol Biochem Parasitol 1996;52:551-559.
25. Singh T, Hoops JF, Biel JH, Hoya WK, Stein RG, Cruz D. Distil hydrazine derivatives of 7-chloroquinoline. J Med Chem 1971;14:532-535.
26. Benazet F. Plasmodium berghi et antimalariques à action de longue durée. Ann Soc Bel Med Trop 1965;45:459-466.
27. Le Bras J, Deloron P, Charmot G. Dichloroquinazine(4-aminoquinoline), effective in vitro against chloroquine resistance Plasmodium falciparum. Lancet 1983;1:73-74.
28. Ohnmacht CJ, Davis F, Lutz RE. Antimalarials V. α-Dibutylaminomethyl and α-(2-piperidyl)-3-quinolinemethanols. J Med Chem 1971;14:17-24.
29. Cowman AF, Deady LW, Deharo E, Desvenes J, Tilley L. Synthesis and activity of some antimalarial bisquinoline methanols. Aust J Chem 1997;50:1091-1096.
30. Yayon A, Ginsburg H. Chloroquine inhibits the degradation of endocytic vesicles in human malaria parasites. Cell Biol Int Rep 1983;7:895-897.
31. Yayon A, Cabantchik Z, Ginsburg H. Identification of the acidic compartment of Plasmodium falciparum infected human erythrocytes as the target of the antimalarial drug chloroquine. EMBO J 1984;3:2695-2700.
32. Fitch CD, Yunis NG, Chevli R, Gonzales Y. High affinity accumulation of chloroquine by mouse erythrocytes infected with Plasmodium berghi. J Clin Invest 1974;54:24-33.
33. Krogstad DJ, Sclesinger PH, Gluzman LY. Antimalarials increase vesicle pH in Plasmodium falciparum. J Cell Biol 1985;101:2302-2309.
34. Ginsburg H, Nissani E, Krugliak M. Alkanisation of the food vacuole of malaria parasites by quinoline drugs and alkyl amines is not correlated with their antimalarial activity. Biochem Pharmacol 1989;38:2645-2654.
35. Gonalez-Noriega A, Grubb JH, Talkad V, Sly WS. Chloroquine inhibits lysosmal enyzmes pinocytosis and enhances lysosomal enzyme secretion by impairing receptor recycling. J Cell Biol 1980;85:839-852.
36. Sando GN, Titus-Dillon P, Hall CW, Neufeld F. Inhibition of receptor mediated uptake of lysosomal enzyme into fibroplast by chloroquine, procaine and ammonia. Exp Cell Res 1979;119:359-364.
37. Krogstad DJ, Schlesinger PH. The basis for antimalarial action: non-weak base effects of chloroquine on acid vesicle pH. Am J Trop Med Hyg 1987;36:213-220.
38. Krogstad DJ, Gluzman IY, Herwaldt BL, Schlesinger PH, Wellems TE. Energy dependence of chloroquine accumulation and chloroquine efflux in Plasmodium falciparum. Biochem Pharmacol 1992;43:57-62.
39. Peters W. Chemotherapy and drug resistance in malaria. London: Academic Press, 1970.
40. De Duve C, De Barsy T, Poole B, Trouet A, Tulkens P, Van Hoof F. Lysosomotrophic agents. Biochem Pharmacol 1974;69:2495-2531.
41. Zarchin S, Krugliak M, Ginsburg H. Digestion of host erythrocyte by malarial parasites is the primary target for quinoline-containing antimalarials. Biochem Pharmacol 1986;35:2435-2442.
42. Homewood CA, Warhurst DC, Peters W, Baggaley VC. Lysosomes, pH and the antimalarial action of chloroquine. Nature 1972;235:50-52.
43. Goldberg DE, Slater AFG, Cerami A, Henderson GB. Haemoglobin degradation in malaaria parsite Plasmodium falciparum. An ordered process in a unique organelle. Proc Natl Acad Sci USA 1990;87:2931-2935.
44. Vander Jagt DL, Hunsaker LA, Campos NM. Characterisation of hemoglobin degrading, low molecular weight protease from Plasmodium falciparum. Mol Biochem Parasitol 1986;18:389-400.
45. Vander Jagt DL, Hunsaker LA, Campos NM. Comparison of proteases from chloroquine-sensitive and chloroquine-resistant strains of Plasmodium falciparum. Biochem Pharmacol 1987;36:3285-3291.
46. Rosenthal PL, Mckerrow JH, Akawa M, Nagasawa H, Leech JH. A malarial cysteine proteinase is necessary for hemoglobin degradation by Plasmodium falciparum. J Clin Invest 1988;82:1560-1566.
47. Ginsburg H, Krugliak M. Quinoline-containing antimalarials mode of action, drug resistance and its reversal. Biochem Pharmacol 1992;43:63-70.
48. Slater AFG, Cerami A. Inhibition by chloroquine of a novel haem polymerase enzyme activity in malarial parasites. Nature 1992;355:167-169.
49. Chou AC, Fitch CD. Heme polymerise: modulation by chloroquine treatment of rodent malaria. Life Sci 1992;51:2073-2078.
50. Bohle D, Dinnebier RE, Madsen SK, Stephens PW. Characterisation of the products of the heme detoxification pathway in malarial late trophozoites by X-ray diffraction. J Biol Chem 1997;272:713-716.
51. Slater AFG, Swiggard WJ, Orton BR, et al. An iron-carboxylate bond links the heme units of the malarial parasites pigment. Proc Natl Acad Sci USA 1991;88:325-329.
52. Slater AFG. Malarial pigment. Exp Parasitol 1992;74:362-365.
53. Blauer G, Akkawi M. Investigations of B- and β-haematin. J Inorg Biochem 1997;66:145-152.
54. Ridley RG, Dorn A, Mutile H, Kansy M. Haem polymerisation in malaria. Nature 1995;378:138-139.
55. Chou A, Fitch CD. Control of heme polymerase by chloroquine and other quinoline derivatives. Biochem Biophy Res Commun 1993;195:422-427.
56. Orjih AU, Fitch CD. Haemozoin production by Plasmodium falciparum variation with strain and exposure to chloroquine. Biochim Biophys Acta 1993;1157:270-274.
57. Egan TJ, Ross DC, Adams PA. Quinoline antimalarial drugs inhibit spontaneous formation of β-hematin (malaria pigment). FEBS Lett 1994;352:54-57.
58. Adams PA, Egan TJ, Silver J, Marsh PJ. The chemical mechanism of β-hematin formation studied by Mossbauer spectroscopy. Biochem J 1996;318:25-27.
59. Banyal HS, Fitch CD. FPIX binding studies and the mode of action of chloroquine against malaria. Life Sci 1982;31:1141-1144.
60. Dorn A, Stoffel R, Matile H, Bubendorf A, Ridley RG. Malarial haemozoin/β-haematin supports haem polymerisation in the absence of proteins. Nature 1995;374:269-271.
61. Fitch CD, Chou AC. Heat-labile and heat stimulatable heme polymerase activities in Plasmodium berghi. Mol Biochem Parasitol 1996;82:261-264.
62. Foley M, Tilley L. Quinoline antimalarials: mechanism of action and resistance. Int J Parasitol 1997;27:231-240.
63. Bendrat K, Berger BJ, Cerami A. Haem polymerisation in malaria. Nature 1995;378:138-139.
64. Sullivan DJ, Gluzman IY, Russell DG, Goldberg DE. On the molecular mechanism of chloroquine's antimalarial action. Proc Natl Acad Sci USA 1996;93:11865-11870.
65. Cohen SN, Phifer KO, Yeilding KL. Complex formation between chloroquine and ferrihaemic acid in vitro, and its effect on the antimalarial action of chloroquine. Nature 1964;202:805-806.
66. Pandey AV, Tekwani BL. Depolymerisation of malaria hemozoin: a novel reaction initiated by blood schizontocidal antimalarials. FEBS Lett 1997;402:236-240.
67. Orjih AU, Banyal HS, Chelvi R, Fitch CD. Hemin lyses malarial parasites. Science 1981;214:667-669.
68. Zhang YA, Hemplemann E. Lysis of malarial parasites and erthrocytes by ferriprotoporphyrin IX-chloroquine and the inhibition of this effect by proteins. Biochem Pharmacol 1987;36:1267-1273.
69. Ribiero M, Augusta O, Ferreira A. Influence of quinoline containing antimalarials in the catalase activity of FPIX. J Inorg Biochem 1997;65:15-23.
70. Ginsburg H, Geary T. Current concepts and new ideas on the mechanism of action of quinoline containing antimalarials. Biochem Pharmacol 1987;36:1567-1576.
71. Foote SJ, Kyle DE, Martin RK, et al. Several alleles of the multidrug-resistance gene are closely linked to chloroquine resistance in Plasmodium falciparum. Nature 1990;345:255-258.
72. Cowman A. Mechanism of drug resistance in malaria. Aust New Zealand J Med 1995;25:837-844.
73. Geary TG, Divo AD, Jensen J, Zangwill M, Ginsburg H. Kinetic modelling of the response of Plasmodium falciparum to chloroquine and its experimental testing in vitro. Biochem Pharmacol 1990;40:685-691.
74. Ginsburg H, Stein WD. Kinetic modelling of chloroquine uptake by malaria infected erythrocytes. Assessment of the factors that may affect drug resistance. Biochem Pharmacol. 1991;41:1463-1470.
75. Bray PG, Hawley SR, Ward SA. 4-Aminoquinoline resistance of Plasmodium falciparum: insights from the study of amodiaquine uptake. Am Soc Pharmacol Exp Ther 1996;50:1551-1558.
76. Sanchez CP, Wunsch S, Lanzer M. Identification of a chloroquine importer in Plasmodium falciparum: differences in import kinetics are genetically linked with the chloroquine resistance phenotype. J Cell Biol 1997;272:2652-2658.
77. + Exchanger determines chloroquine uptake in Plasmodium falciparum. J Cell Biol 1998;140:335-345.
78. + antiport of Plasmodium falciparum. J Cell Physiol 1993;50:1559-1566.
79. + exchanger. J Clin Invest 1986;78:859-864.
80. Martin SK, Odula AM, Milhous WK. Reversal of chloroquine resistance by verapamil. Science 1987;235:899-901.
81. Ohsawa K, Tanabe K, Kimata I, Mika A. Ultrastructural changes associated with the reversal of chloroquine resistance by verapamil in Plasmodium chabaudi. Parasitol Today 1991;103:185-189.
82. Kyle DE, Milhous WK, Rossan RN. Reversal of Plasmodium falciparum resistance in Panamanian Aotus monkeys. Am J Trop Med Hyg 1993;48:126-133.
83. Riordan JR, Deuchars K, Kartner N, Alon N, Trent J, Ling V. Amplication of P-glycoprotein genes in multi-drug resistant mammalian cell lines. Nature 1985;316:817-819.
84. Cowman AF, Galatis D, Thomspon JK. Selection of mefloquine resistance in Plasmodium falciparum in linked to amplication of the pfmdr 1 gene and cross-resistance to halofantrine and quinine. Proc Natl Acad Sci USA 1994;91:1143-1147.
85. Wellems TE, Panton LT, Gluzman IY, et al. Chloroquine resistance not linked to the mdr-like genes in Plasmodium falciparum. Nature 1990;345:253-255.
86. Wilson CM, Volkman SK, Thaithong S, et al. Amplification of pfmdr 1 associated with mefloquine and halofantrine resistance in Plasmodium falciparum from Thailand. Mol Biochem Parasitol 1993;57:151-160.
87. Gluzman IY, Schlesinger PH, Krogstad DJ. Inoculum effect with chloroquine and Plasmodium falciparum. Antimicrob Agents Chemother 1987;31:32-36.
88. Hawley SR, Bray PG, O'Neill PM, Naisbitt DJ, Park BK, Ward SA. Manipulation of the N-alkyl substituent in amodiaquine to overcome the verapamil sensitive chloroquine resistance mechanism. Antimicrob Agents Chemother 1996;40:2345-2349.
89. Ferrari V, Cutler DJ. Simulation of kinetic data on the influx of chloroquine by erythrocytes infected with Plasmodium falciparum. Evidence for a drug-importer in chloroquine sensitive strains. Biochem Pharmacol 1991;42:69-79.
90. Bray PG, Hawley SR, Mungthin M, Ward SA. Physiochemical properties correlated with drug resistance and the reversal of drug resistance in Plasmodium falciparum. Mol Pharmacol 1996;50:1559-1566.